Data and Terminal Security J12010
description of job
1. Responsible for the construction of the company's terminal security tools, including but not limited to the requirements analysis, implementation and deployment and daily operation and maintenance of file encryption, file watermarking, and desktop security management tools;
2. Responsible for the construction of company data leakage prevention (DLP) security work;
3. Responsible for terminal security management and control of the company's overall office environment, configure security management and control strategies, formulate security baselines and strategy formulations, promote, optimize and maintain;
4. Responsible for the optimization, operation and maintenance of the company's terminal security management system;
5. Responsible for identification, analysis and treatment of security risks in the office terminal environment;
6. Responsible for the construction and operation of the company's terminal anti-leakage.
1. University degree or above (undergraduate degree requires 3 years or above work experience, postgraduate 1 year or above work experience);
2. Have working experience in safety technology or safety operation and maintenance;
3. Experience in maintenance management such as anti-virus, desktop access, patch management;
4. Familiar with various desktop operating systems and desktop security management software;
5. Have a preliminary grasp of one of the programming or scripting languages of Python, JAVA, and Shell;
6. Good communication and teamwork skills, rapid learning ability, and exploration spirit of cutting-edge technology and application practice;
1.Have experience in terminal security construction and operation and maintenance
2, with one or more of CISSP, CISA, CCSP and other certificates
Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales. It is a well-known domestic R & D and production base for liver health drugs. It is a national key high-tech enterprise and a national torch plan. Backbone enterprises, ranked 16th in the Top 100 Chinese Pharmaceutical Industry Enterprises in 2016 (selected and released by China Pharmaceutical Industry Information Center).
Zhengda Tianqing always regards scientific and technological innovation as an important strategy for enterprise development, and is one of the pharmaceutical companies with a large investment in innovative drug research in China. Zhengda Tianqing regards the research institute as the innovation carrier, and has established high-level R & D platforms such as "Jiangsu New Liver Disease Engineering and Technology Research Center", "Postdoctoral Research Station", and "Nationally Recognized Enterprise Technology Center", and has continuously enhanced its independent innovation capabilities. With the development of enterprises and the enhancement of R & D capabilities, Zhengda Tianqing has invested more than 1 billion yuan in R & D expenses and will gradually align with multinational companies. At present, the institute has more than 180 research projects, including more than 30 new drugs and more than 20 biological drugs.
Zhengda Tianqing has three production bases in Lianyungang, covering a total area of more than 800 acres, including a hatching base covering an area of 160 acres, an API base covering over 200 acres, and a preparation base covering 480 acres. Zhengda Tianqing Preparation Base obtained the country's first new GMP certificate. The solid preparation workshop passed the European Union certification and the EU-approved GMP certificate issued by the German Drug Administration. The obtaining of these certificates indicates that the quality and management level of pharmaceutical production of enterprises are at the forefront of the national pharmaceutical industry. At present, Chia Tai Tianqing is preparing for the four major fist products to enter the international market. In the future, these drugs will become a new weapon for Chia Tai Tianqing to crack the international market.
The field of treatment of Zhengda Tianqing products involves liver disease, tumor, respiratory, infection, digestion and other diseases. 16 products with annual sales of over 100 million yuan have formed a "product group of 100 million yuan", of which products with annual sales of over 2 billion yuan 2 These are the national first-class new medicine magnesium isoglycyrrhizinate injection (Tianqing Ganmei) and the first domestic marketed entecavir dispersible tablet (Runzhong). In addition to the field of strong liver disease, a unique product line has also been formed in the field of anti-tumor. The blood tumor products decitabine, imatinib, and dasatinib are the first in the country; capecitabine, a solid tumor product, was approved for marketing. Anlotinib, the original and innovative drug in the Chinese tumor field that has attracted much attention, is officially on the market and is expected to become the standard drug for third-line treatment of patients with advanced non-small cell lung cancer. Respiratory, antibiotic, endocrine and other fields will also be the focus of the company's future development.
In the future development, Zhengda Tianqing Pharmaceutical will continue to strengthen the building of core competitiveness, establish a sound scientific and efficient research and development system, so that the company's research and development level is always in line with the international frontier. Develop the company into a large-scale pharmaceutical group with the scientific research strength among the top five pharmaceutical companies in the country and the top ten in the country with comprehensive strength; and launch an internationalization strategy to build the company into a scientific and technological, pharmaceutical-based international company.
Lianyungang City Address: No. 369 Yuzhou South Road, Lianyungang City, Nanjing Address: Building 9, District 699-8, Xuanwu Avenue, Xuanwu District, Nanjing (Xuzhuang Software Park R & D Zone 1)
Job posting company
Zhengda Tianqing Pharmaceutical Group Co., Ltd.
Enterprise nature: joint venture
Enterprise size: 10,000 or more
Year of establishment: 1997
Enterprise website: http://www.cttq.com
Business Address: 369 Yuzhou South Road
- 医药代表（日照）J12036 6001-8000 Medical Representative (Rizhao) J12036
- 临床监查员-武汉J11409 6001-8000 clinical monitor-Wuhan J11409
- 医药代表（天门）J11957 8001-10000 Medical Representative (Tianmen) J11957
- 研发岗/实验岗J12051 8001-10000 R & D post / experiment post J12051
- 临床监查员（IIT/IV）（上海）J11631 8001-10000 Clinical Supervisor (IIT / IV) (Shanghai) J11631
- 血液肿瘤推广专员（淮安）J11707 8001-10000 Blood Cancer Promotion Specialist (Huai'an) J11707
- 临床监查员（IIT/IV）（苏州）J12048 8001-10000 Clinical Supervisor (IIT / IV) (Suzhou) J12048
- 临床监查员-昆明J11682 6001-8000 Clinical Supervisor-Kunming J11682
- 研发系统管理工程师J11955 8001-10000 R & D system management engineer J11955
- 知识产权专员助理J11568 6001-8000 Assistant to Intellectual Property Commissioner J11568
Related job recommendations
区域经理 特色专科项目运营总监 地区经理（江苏） 地区经理（江苏） 培训讲师 学术专员 冻干粉针剂车间工艺员 研发岗/实验岗J12051 地区经理（江苏） 处方药事业部销售经理（江苏） Relevant positions in Jiangsu: Regional Manager Specialty Project Operation Director Regional Manager (Jiangsu) Regional Manager (Jiangsu) Training Lecturer Academic Specialist Freeze-dried powder injection workshop process technician R & D post / Experiment post )
吉林万通药业集团药品经销有限公司 江苏吉贝尔药业有限公司 鱼跃医疗 徐州新沂市钟吾医院 丽珠医药集团股份有限公司 无锡道生中医文化发展有限公司 广东众生药业股份有限公司苏北办事处 江苏大丰同仁医院 江苏南中医丰盛健康城有限公司 江苏南京溧水区中医院 Jiangsu Recruitment Enterprise: Jilin Wantong Pharmaceutical Group Drug Distribution Co., Ltd. Jiangsu Jibel Pharmaceutical Co., Ltd. Yuyue Medical Xuzhou Zhongwu Hospital Lizhou Pharmaceutical Group Co., Ltd. Wuxi Daosheng Traditional Chinese Medicine Cultural Development Co., Ltd. Guangdong Zhongsheng Pharmaceutical North Jiangsu Co., Ltd. Jiangsu Dafeng Tongren Hospital Jiangsu South Traditional Chinese Medicine Fengsheng Health City Co., Ltd. Traditional Chinese Medicine Hospital of Wushui District , Nanjing , Jiangsu